Skip to main content
    T

    Tarsus Pharmaceuticals Inc (TARS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $78.68
    -1.60 (-1.99%)

    Market Cap: $3.96B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tarsus Pharmaceuticals Inc (TARS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Tarsus Pharmaceuticals reported revenue of $451.36M for the fiscal year ended Dec 31, 2025, up 146.7% from the year before. That year, net income was -$66.42M with a net margin of -14.7%, operating cash flow was -$12.45M and free cash flow was -$22.31M. The quarter ended Sep 30, 2026 had revenue of $194.57M and net income of -$668.33M.

    Revenue and Margins

    The operating margin was -15.7% in the fiscal year ended Dec 2025, the highest of the 3 years shown with an operating margin.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$451.36M+146.7%93.2%-15.7%-14.7%
    Dec 2024$182.95M+948.6%93.0%-65.9%-63.2%
    Dec 2023$17.45M-32.4%90.9%-820.5%-778.9%
    Dec 2022$25.82M-54.7%96.3%-242.9%-240.5%
    Dec 2021$57.03MN/A96.4%-21.3%-24.2%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$451.36M$182.95M$17.45M$25.82M$57.03M$0$0$0
    Cost of revenue$30.68M$12.83M$1.59M$955.00K$2.08M$0$0$1.00K
    Gross profit$420.68M$170.13M$15.85M$24.86M$54.95M$0$0-$1.00K
    Research and development$64.32M$53.39M$50.31M$42.62M$41.71M$18.83M$3.16M$901.00K
    Operating income-$70.97M-$120.57M-$143.16M-$62.71M-$12.16M-$27.00M-$4.30M-$1.35M
    Net income-$66.42M-$115.55M-$135.89M-$62.09M-$13.83M-$26.81M-$4.67M-$1.32M
    EBITDAN/AN/AN/AN/AN/A-$26.90MN/A-$1.32M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$194.57M$173.91M$162.05M$151.67M$118.70M$102.66M$78.33M$66.41M$48.12M$40.81M$27.61M$13.08M
    Gross profit$180.68M$161.80M$152.66M$140.74M$110.39M$96.42M$73.12M$61.48M$44.88M$37.81M$25.96M$11.86M
    Operating income-$662.09M-$19.91M-$6.12M-$7.98M-$14.53M-$22.18M-$26.28M-$24.42M-$25.16M-$33.30M-$37.68M-$44.45M
    Net income-$668.33M-$18.55M-$6.97M-$8.37M-$12.59M-$20.34M-$25.12M-$23.11M-$23.42M-$33.29M-$35.73M-$41.90M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded long-term debt of $72.44M by $111.20M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$562.16M$376.99M$265.49M$227.86M$178.91M$171.97M$58.32M$2.39M
    Current assets$522.78M$356.70M$256.13M$225.38M$175.95M$170.66M$58.03M$2.38M
    Cash and equivalents$183.64M$94.82M$224.95M$71.66M$171.33M$168.13M$57.95M$2.35M
    Total liabilities$218.73M$152.46M$68.50M$34.96M$12.18M$5.99M$919.00K$3.74M
    Short-term debtN/A$608.00K$398.00K$721.00K$1.31M$282.00K$64.00KN/A
    Long-term debt$72.44M$71.84M$29.82M$19.43M$0N/AN/AN/A
    Shareholder equity$343.43M$224.53M$196.99M$192.90M$166.73M$165.98M-$6.00M-$1.35M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$505.50M$611.14M$581.13M$562.16M$534.56M$494.99M$500.75M$376.99M$376.30M$376.84M$349.28M$265.49M
    Total liabilities$401.47M$264.41M$232.18M$218.73M$199.48M$162.38M$158.29M$152.46M$138.82M$124.60M$74.07M$68.50M
    Cash and equivalents$136.53M$204.59M$102.19M$183.64M$112.72M$96.65M$175.79M$94.82M$176.21M$181.09M$193.71M$224.95M
    Shareholder equity$104.03M$346.73M$348.95M$343.43M$335.08M$332.61M$342.46M$224.53M$237.48M$252.25M$275.21M$196.99M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$12.45M-$83.03M-$117.49M-$49.03M$3.75M-$21.14M-$3.67M-$1.18M
    Capital expenditures$9.86M$1.57M$1.50M$506.00K$586.00K$456.00K$175.00K$7.00K
    Free cash flow-$22.31M-$84.59M-$119.00M-$49.54M$3.16M-$21.59M-$3.85M-$1.19M
    Investing cash flow-$42.12M-$199.19M$140.60M-$144.63M-$586.00K-$456.00K-$175.00K-$7.00K
    Financing cash flow$143.39M$154.66M$130.18M$93.99M$21.00K$131.77M$59.45M$3.56M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$6.00M$61.22M-$24.65M$19.33M$18.26M-$29.39M-$20.65M-$22.18M-$8.65M-$14.40M-$37.79M-$39.34M
    Capital expenditures$1.21M$4.07M$5.82M$6.36M$1.57M$1.34M$590.00K$72.00K$282.00K$1.04M$174.00K$4.00M
    Free cash flow-$7.21M$57.15M-$30.47M$12.97M$16.69M-$30.73M-$21.24M-$22.25M-$8.93M-$15.44M-$37.96M-$43.34M
    Last 12 quarters

    Frequently Asked Questions About TARS

    What is Tarsus Pharmaceuticals' annual revenue?

    Tarsus Pharmaceuticals reported revenue of $451.36M for the fiscal year ended Dec 31, 2025.

    How fast is Tarsus Pharmaceuticals' revenue growing?

    Revenue was up 146.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 159.5%.

    Is Tarsus Pharmaceuticals profitable?

    No. Tarsus Pharmaceuticals reported net income of -$66.42M for the fiscal year ended Dec 31, 2025, with a net margin of -14.7%.

    How much free cash flow does TARS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$12.45M minus capital expenditures of $9.86M produced free cash flow of -$22.31M.

    How much debt does Tarsus Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $72.44M and cash and equivalents of $183.64M.